Table 2

Antiretroviral Classes with Newly Approved Drugs in Treatment-Experienced Patients

Class	Drug Name	Clinical Status	Pivotal Clinical Studies	Comments
Entry Inhibitors	Maraviroc[a] (Selzentry®)	FDA-approved	Phase IIb/III studies (MOTIVATE I & II)[12,13]: (N = 601, MOTIVATE I; N = 475, MOTIVATE II) triple-class, treatment experienced patients with mean age of 45 years, 90% males, median CD4 cell count of 150-180 cells/mm^3 and a mean HIV viral load of ~ 65,000 copies/mL. Results: 24-week results showed significantly better virologic responses over 24 weeks with maraviroc-treated patients (45.6%-48.5% of twice-daily dosing arm patients achieved viral loads < 50 copies/mL) compared with placebo-treated patients (20.9%-24.6% of patients achieved viral loads < 50 copies/mL; $P < 0.0001$)	-Maraviroc should be considered for use in treatment-experienced patients who have only R5 virus and who are naive to CCR5 inhibitors. -Usual dose range: 150-600 mg bid
Integrase Inhibitor	Raltegravir (Isentress®)	FDA-approved	Phase III studies (BENCHMARK I & II)[4,5] (total N = 699) triple-class, treatment-experienced patients, failed current ARVs, with detectable viremia Results: 24-week results showed significantlybetter virologic responses with raltegravir-treated patients (63% of patients achieved viral loads < 50 copies/mL) compared with placebo-treated patients (34% of patients achieved viral loads < 50 copies/mL) when added to OBT.	-Raltegravir should be considered for use in treatment-experienced patients who are naive to integrase inhibitors -Usual dose: 400 mg bid
NNRTI	Etravirine (TMC-125)	FDA-approved	Phase III studies (DUET I & II)[14,15] (N = 612 in DUET I; N = 591 in DUET II) triple-class, treatment-experienced patients with at least one NNRTI-associated resistance mutation and at least 3 primary PI mutations,failure of current ARV regimen. All patients received darunavir with low-dose ritonavir, along with investigator-selected NRTIs. Enfuvirtide was considered as an optional agent. Results: 24-week results showed significantly better virologic patients (56%-62% of patients achieved viral loads < 50 copies/mL) compared with placebo-treated patients (39%-44% of patients achieved viral loads < 50 copies/mL; P = 0.005 in DUET I; P = 0.0003 in DUET II)	-Expanded access program available since July 2007 -Usual dose: 200 mg bid with food

[a]The entry inhibitors are a heterogeneous group that includes agents that act at several stages in the entry process. Maraviroc is a CCR5 antagonist
OBT-optimized background therapy (a regimen of active antiretroviral agents tailored to individual patients, selected by their physicians as most likely to be of benefit); ARV-Antiretroviral